Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BRISTOL-MYERS SQUIBB COMPANY

(BMY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Bristol-Myers Squibb's Supplemental Biologics License Application for Drug Co-Developed With Merck & Co. Gets FDA Priority Review

12/03/2021 | 07:29am EST


© MT Newswires 2021
All news about BRISTOL-MYERS SQUIBB COMPANY
01/11Evotec, Bristol Myers Expand Neurogenerative Partnership to Include New Targeted Protei..
MT
01/11Biomica Announces Clearance for First-in-Human Phase I Study of BMC-128 in Combination ..
AQ
01/11Evogene's Biomica Gets Israeli Nod To Move Ahead With Cancer Trial
MT
01/10BioAlta, Bristol Myers Squibb Partnering on Potential Cancer Treatments
MT
01/10BioAtla Announces Clinical Collaboration with Bristol Myers Squibb to Study Mecbotamab ..
PR
01/10Bioatla, Inc. Enters into a Clinical Collaboration with Bristol Myers Squibb to Investi..
CI
01/10Century Therapeutics, Bristol Myers Squibb Sign Cancer Research Collaboration Agreement
MT
01/10Century Therapeutics Shares Rise 12% Premarket After Bristol Myers Deal
DJ
01/10BRISTOL MYERS SQUIBB : JP Morgan Presentation
PU
01/10BRISTOL MYERS SQUIBB CO : Regulation FD Disclosure, Financial Statements and Exhibits (for..
AQ
More news
Analyst Recommendations on BRISTOL-MYERS SQUIBB COMPANY
More recommendations
Financials (USD)
Sales 2021 46 408 M - -
Net income 2021 6 271 M - -
Net Debt 2021 28 505 M - -
P/E ratio 2021 22,0x
Yield 2021 3,03%
Capitalization 144 B 144 B -
EV / Sales 2021 3,72x
EV / Sales 2022 3,40x
Nbr of Employees 30 250
Free-Float -
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | BMY | US1101221083 | MarketScreener
Technical analysis trends BRISTOL-MYERS SQUIBB COMPANY
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 64,93 $
Average target price 71,79 $
Spread / Average Target 10,6%
EPS Revisions
Managers and Directors
Giovanni Caforio Chairman & Chief Executive Officer
David V. Elkins Chief Financial Officer & Executive Vice President
Paul von Autenried Chief Information Officer & Executive VP
Rupert J. Vessey Executive VP-Research & Early Development
Joseph E. Eid Senior VP & Head-Global Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
BRISTOL-MYERS SQUIBB COMPANY4.14%144 122
JOHNSON & JOHNSON-1.35%441 855
ROCHE HOLDING AG-3.72%323 901
PFIZER, INC.-6.94%308 427
ABBVIE INC.0.35%240 202
ELI LILLY AND COMPANY-11.62%221 317